In race against extinction, new agreement supports Harvard’s work to analyze and digitize its medicinal plant collections

Researchers at the Andrew G Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology are engineering synthetic antibiotics that directly target bacteria which cause lower respiratory tract and skin and soft tissue infections.

A look back at moments in 2023 where researchers and industry leaders came together to connect and learn; strategic collaborations, research agreements and accelerator funding were announced; and translational research made it out of the labs for societal impact.

Harvard University joins Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center as the initial four academic institutions to participate in LAB eN².